The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- NPC News
- Pandemic Response
- (-) Patient Centered Formulary & Benefit Design
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Showing 88 Results
Shared Decision-Making Makes Sense for Patients and the Bottom Line
If shared decision-making is good for patients, is it good for the bottom line as well? A new study from NPC and Real Chemistry sheds light.
Impact of Shared Decision-Making and Patient Decision Aids on Health Care Cost and Utilization in the US: A Systematic Review
Shared decision-making and patient decision aids may reduce costs or improve utilization but not consistently across settings and diseases, according to a new systemic literature review by…
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
Study shows the impact of a more holistic approach to assessing value and how it can help address gaps within conventional value assessment.
NPC Comments on CMS's Hospital Outpatient Prospective Payment Systems Proposed Rule
NPC comments raise potential concerns as CMS states its intent to make significant changes to the payment rate for drugs purchased through the 340B program.
NPC Comments on CMS CY 2023 Payment Policies under the Physician Fee Schedule
NPC's comments offer input on CMS's implementation of the Discarded Drug Refund Policy, support continuing the add-on payment for at-home COVID-19 vaccinations, and provide recommendations on the…
NPC Comments on CMS Request for Information on the Medicare Program
NPC's comments to CMS's recent request for information on the Medicare program focus on access, innovation and the importance of patient engagement.
Predictors of Adherence to Oral Anticancer Medications: An Analysis of 2010-2018 U.S. Nationwide Claims
Low-income Medicare patients who face high out-of-pocket costs are less likely to remain adherent to oral anticancer medications. This research shows the need for strategies to address adherence and…
Predictors of Adherence to Oral Anticancer Medications: The Impact of Out-of-Pocket Costs
Biopharmaceutical innovation has led to an increase in the availability of oral anticancer medications (OAMs), but research shows that almost half of patients on OAMs do not take their medications as…
Impact of Real-Time Benefit Tools on Patients’ Access to Medications: A Retrospective Cohort Study
Study finds the use of Real-Time Prescription Benefit Tools results in higher fill rates and lower cancellation rates.
Bringing the Patient Voice Into Benefit Design
Diverse populations have diverse needs, and that's why NPC Chairman Steven Romano says benefit design and coverage policies should start with the patient in mind.
Wage and Its Impact on Access and Adherence to Specialty Medications
Research found that lower-wage employees faced higher out-of-pocket costs, were less likely to use specialty medicines than higher-income workers and relied more regularly on emergency room care.
Specialty Drug and Healthcare Utilization Vary by Wage Level in Employer-Sponsored Health Plans
This research shows that low-wage employees are less likely use autoimmune medicines than employees who earn more despite a higher prevalence of autoimmune conditions in low-wage employees. These…
Comments to FTC on Business Practices of PBMs and Their Impact on Pharmacies and Consumers
NPC submitted comments to the Federal Trade Commission encouraging the study of anti-competitive business practices of pharmacy benefit managers and their impact on drug affordability and access.
NPC’s John O’Brien Discusses The Myth of Average on AiArthritis Voices 360 Talk Show
On a recent episode of AiArthritis Voices 360 Podcast, John M. O’Brien discusses NPC’s research on the importance of fostering biopharmaceutical innovation and improving patient access to the right…
Addressing the Needs of People Living With Autoimmune Disorders: A Conversation With Molly Murray
NPC had the opportunity to speak with Molly Murray, president and CEO of the Autoimmune Association, to learn more about the importance of understanding how individual patient differences affect the…
Why Patients Are Paying More at the Pharmacy Counter in Early 2022 - And What We Can Do to Fix It
NPC Immediate Past Board Chair Mike Ryan and CSO Sharon Phares explore policy solutions to ensure patients can have predictable and affordable out-of-pocket costs for medicines.
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2023
NPC offers research-based comments to improve patient access to care and health equity.
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and continued…
How the Myth of Average Persists in Health Benefits
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.